Adverse Event Clinical Research, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-ae-research-ig/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
Generated Narrative: AdverseEvent
Resource AdverseEvent "adverse-event-compass-ex1b"
Profile: Adverse Event Clinical Research
Adverse Event Grade: Grade 1 Mild Adverse Event (NCI Thesaurus#C41338)
status: completed
actuality: actual
code: Alanine aminotransferase (ALT) decreased to 60 (Medical Dictionary for Regulatory Activities#10001551 "Alanine aminotransferase increased")
subject: Patient/patient-example-kaitlyn-b " BOUNCE"
occurrence: 2020-05-20 --> 2020-06-10
resultingEffect: : Reference to Observation of Alanine aminotransferase (ALT) decreased to 60
seriousness: Non-serious (AdverseEventSeriousness#non-serious)
outcome: Recovered/Resolved (NCI Thesaurus#C49498)
recorder: Practitioner/practitioner-oncology-nurse-jane " NURSE"
Function | Actor |
authenticator (ParticipationType#AUTHEN) | Practitioner/practitioner-owen-oncologist " ONCOLOGIST" |
study: ResearchStudy/clinical-trial-example-compass
expectedInResearchStudy: true
suspectEntity
instance: MedicationAdministration/medication-administration-kadcyla
Causalities
EntityRelatedness Possibly Related (NCI Thesaurus#C53258)
suspectEntity
instance: MedicationAdministration/medication-administration-tucatinib
Causalities
EntityRelatedness Possibly Related (NCI Thesaurus#C53258)
mitigatingAction
item: MedicationAdministration/medication-administration-kadcyla-reduced
mitigatingAction
item: MedicationAdministration/medication-administration-tucatinib-reduced
Item[x] |
: Supporting info would have context such as an Reference to Observation of Alanine aminotransferase (ALT) decreased to 60 |
note: treatment given with reduced dose per protocol guidelines